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A quinazoline-based HDAC inhibitor aﬀects gene
expression pathways involved in cholesterol
biosynthesis and mevalonate in prostate cancer
cells†
Z. Lin,a K. S. Bishop,*a H. Sutherland,a G. Marlow,b P. Murray,a W. A. Dennya and
L. R. Fergusonab
Chronic inflammation can lead to the development of cancers and resolution of inflammation is an
ongoing challenge. Inflammation can result from dysregulation of the epigenome and a number
of compounds that modify the epigenome are in clinical use. In this study the anti-inflammatory and
anti-cancer eﬀects of a quinazoline epigenetic-modulator compound were determined in prostate
cancer cell lines using a non-hypothesis driven transcriptomics strategy utilising the Aﬀymetrix
PrimeViews Human Gene Expression microarray. GATHER and IPA software were used to analyse the
data and to provide information on significantly modified biological processes, pathways and networks.
A number of genes were diﬀerentially expressed in both PC3 and DU145 prostate cancer cell lines. The
top canonical pathways that frequently arose across both cell lines at a number of time points included
cholesterol biosynthesis and metabolism, and the mevalonate pathway. Targeting of sterol and mevalonate
pathways may be a powerful anticancer approach.
1. Introduction
Although inflammation is a necessary immune response, chronic
inflammation can lead to the development of cancers as well as
other chronic diseases, and there are ongoing eﬀorts to either
block pro-inflammatory mediators or to stimulate resolution of
inflammation.1 Deregulation of the epigenome can result in
a range of chronic diseases associated with inflammation, and
a number of compounds that modify the epigenome are in
clinical use today.2
Chromatin remodelling plays a key role in gene expression,
and epigenetic modifications may be as important as mutations,
insertions and deletions in tumour development and progression.3
Unlike genetic mutations, epigenetic changes that have resulted in
gene activation or silencing can sometimes be reversed by small
molecules that modify the epigenome. One such group of small
molecules are the histone deacetylase (HDAC) inhibitors. HDACs
influence the expression of a number of key enzymes involved
in pathways associated with apoptosis, cell cycle, tumour cell
proliferation and inflammation, amongst others4 and tumour
progression is associated with an increase in HDAC activity.5
However, although HDAC inhibitors have an impact on tumour
and T cell lymphomas rather than non-malignant cells, their
mechanism of action remains unclear.4
HDACs and histone acetyltransferases (HATs) act in opposition
tomodify chromatin and thus control gene expression.6 HDACs can
repress transcription by bringing about chromatin condensation in
response to the removal of acetyl groups from histone tails.6 Not
only have HDACs been found to be aberrantly recruited to
‘‘inappropriate’’ loci, but abnormal expression of HDACs 1, 2,
3 and 6 have been reported in numerous types of cancer e.g.
gastric, breast, prostate, colorectal and cervical.6 SN30028 is an
HDAC inhibitor that was identified from an in-house compound
library.7 SN30028 (Fig. 1) is regarded as a quinazoline drug and
was selected from the aforementioned compound library based
on its anti-inflammatory activity and the strength of HDAC
inhibition.7,8
Fig. 1 Chemical structure of SN30028.
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SN30028 decreased the activity of HDAC 1, 3 and 6 by 23%,
76% and 48% respectively.9 HDACs 1 and 3, HDAC class I
compounds, are restricted to the nucleus and are believed to
play a key role in cell survival and proliferation.10 Loss of HDAC
1 activity results in an overall reduction of deacetylase activity,
reduced proliferation rates and increased levels of the cyclin-
dependent kinase inhibitors p21 and p27.11 HDAC 3 is important
as it mediates gene expression of tumour necrosis factor (TNF)
as well as the expression of other genes.12
HDAC 6 belongs to the HDAC Class 2b group of compounds
and is unique as it has two catalytic domains and a zinc finger.6
HDAC 6 is of interest as it helps to protect against cellular stress
by the regulation of heat shock protein 90 and alpha tubulin
and down-regulation can bring about apoptosis and inhibition
of metastasis.13,14
Determining the eﬀect of a particular compound on cancer
cell lines can be challenging as eﬀects on any one gene can be
small, and these eﬀects can also be broad. For this reason the
anti-inflammatory and anti-cancer eﬀects of a quinazoline
epigenetic-modulator compound were determined, in prostate
cancer cell lines, using a transcriptomics approach.
One advantage of transcriptomics is that experimental design
is non-hypothesis driven, and provides suﬃcient sensitivity
and breadth to examine the expression of thousands of genes
simultaneously.15 The Aﬀymetrix PrimeView GeneChip Human
Microarray was used as it is a ‘‘perfect-match-only’’ (probe
to transcript) array16 and therefore the false signal changes
referred to by Li et al.17 are less likely to arise.
In addition biological processes are likely to be represented
by complex networks consisting of multiple signalling modules
rather than a series of linear pathways18 and thus a transcriptomics
approach, followed by network analysis, was deemed preferable.
The aim of this study was to determine the eﬀect of SN30028 on
diﬀerential gene expression in prostate cancer cell lines with a
particular focus on inflammation and epigenetic modulation.
Compounds, that restore histone acetylation, have potential as
anti-inflammatory and anti-cancer drugs,19 and we show evidence
that the known7 quinazoline-based HDAC inhibitor SN30028
(Fig. 1) influenced cholesterol biosynthesis and mevalonate
pathways.
2. Methods
2.1 Cell culture
The prostate cancer cell lines PC3, DU145 and LNCaP were
obtained from the American Type Culture Collection (VA, USA)
and maintained in Alpha 5 minimum essential media (Gibco,
Invitrogen Corporation, New York, USA) with 10% fetal calf
serum (Morgate Biotech, Hamilton, New Zealand) and 100 IU
penicillin/streptomycin (Sigma Chemical Company, St Louis,
MO, USA). Cells were cultured in a water jacketed incubator
(Thermo Fisher Scientific, MA, USA) at 37 1C with 5% CO2, and
passaged twice weekly. The 50% inhibitory concentrations
(IC50s) for SN30028 and a number of other compounds were
established and the anti-proliferative activity was determined
relative to the reference drugs suberoylanilide hydroxamic acid
(SAHA) (Sigma Chemical Company, St Louis, MO, USA) and
50-aza-2-deoxycytidine (Sigma-Aldrich, St Louis, MO, USA).
Dimethyl sulphoxide (DMSO) (Merck, Darmstadt, Germany)
was used as a solvent for the compounds tested and hence
was also used as a control. The IC50s were performed on PC3,
DU145 and LNCaP using the sulforhodamine B colorimetric
assay.20 Three independent experiments were performed in
quadruplicate.
2.2 HDAC activity
HDAC activity was assessed from total protein extracted from
DU145, PC3 and LNCaP cells following treatment for 24 hours
with a number of compounds (TSA, SAHA, SN30028, SN30029,
SN30140, SN29887, SN29984, SN30711, 5-aza-2-deoxycitidine
(5AZA)) (Sigma Aldrich, St Louis, USA) at their respective IC50
concentrations. Total protein was extracted from each treated
cell line grown in P100 plates. The cells were washed with PBS,
lysed (lysis buﬀer containing 1% Triton X-100 (Sigma Aldrich,
St Louis, USA)), frozen, then thawed and removed to a micro-
centrifuge tube, whereupon the cells were centrifuged and the
supernatant collected. Protein concentration was assessed
using the bicinchoninic acid (Sigma Aldrich, St Louis, USA)
protein assay (as outlined in Lin et al.).7
Using the manufacturer’s protocol the HDAC Fluorometric
Activity Assay (BIOMOL International – Cayman Chemical, Ann
Arbor, USA) was used to measure the effect of compounds on
HDAC activity from the extracted protein. Three independent
experiments were performed in duplicate.
2.3 Transcriptomics
Two prostate cancer cell lines, namely DU145 and PC3 cells,
were treated with SN30028 and harvested at 4, 24 and 96 hours
after dosing (Fig. 2). In addition, cell lines were incubated with
an equivalent amount of water for each of the three time points.
These served as controls. DU145 and PC3 were chosen ahead of
LNCaP as the aforementioned were shown to have greater
sensitivity to HDAC inhibition than LNCaP9 (see Section 3.1)
A QIAshredder (Qiagen, MD, USA) was used to disrupt the cells
and an RNeasy Mini kit (Qiagen, MD, USA) was used to isolate
the RNA in triplicate, following the manufacturer’s recommended
protocol. The quantity and quality of RNA was determined using the
NanoDrop ND 1000 spectrophotometer (NanoDrop Technologies,
Wilmington, USA) and the Experion RNA StdSens Analysis Kit
(Biorad, Hercules, USA) respectively. Approximately 500 ng of RNA
with a RIN value of48 were required for the PrimeViews Human
Gene Expression arrays (Aﬀymetrix, CA, USA). The RNA was reverse
transcribed, biotin labelled, fragmented, hybridised to the gene chip
and scanned21 by the Centre for Genomics and Proteomics (New
Zealand Genomics Ltd, University of Auckland, New Zealand).
The PrimeViews Human Gene Expression array uses 530 000
probes covering 36000 transcripts and variants located in more
than 20 000 genes.22 Transcripts were measured independently
by usingmultiple probes. The level of gene expression was associated
with the probe/s targeting that specific gene and following
adjustment for the solvent/media controls, diﬀerential gene
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expression was calculated. The workflow for the analysis of the
gene expression array data is outlined in Fig. 2.
Confirmation of the microarray results was carried out using
quantitative reverse transcription polymerase chain reaction
(qRT-PCR) and 27 statistically significant diﬀerentially expressed
genes were selected for validation. The 27 TaqMan probe sets
were obtained from ThermoFisher (Pleasanton, USA). The afore-
mentioned RNA (Section 2.2) was isolated from DU145 and PC3
following treatment for 4 and 24 h, converted to cDNA using a
Quantitect Reverse Transcription Kit (Qiagen, Victoria, Australia)
and PCR was performed (on the three biological repeats as well as
non-template controls) on an Applied Biosystems 7900 thermo-
cycler (Waltham, USA). Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), hypoxanthine phosphor-ribosyltransferase
1 (HPRT1), and b-actin (ACTB) were tested for assessment as
normalisation genes for RNA expression. A standard curve was
calculated from technical triplicates using SDS2.3 and RQ
Manager 2.2 software (Applied Biosystems, USA). The relative
expression of each of the genes was calculated as fold change
using a delta delta cycle threshold (Ct) method.24 Thereafter
fold changes from the Aﬀymetrix and qRT-PCR experiments
were compared.
2.4 Data analysis
To identify the diﬀerentially expressed genes, the data from the
microarray experiments were subjected to Robust Multiarray
Analysis25 to assess for quantile normalisation and then filtered
based on the following parameters: (adjusted p value o0.05;
fold change41.5). The ‘‘Limma’’ package within the statistical
language R26 was used to analyse the CEL files generated by the
Aﬀymetrix GeneChip Instrument System (Aﬀymetrix, MD, USA).
Gene expression values were based on the absorbance values of
the probes targeting each specific gene. Changes in average
gene expression in response to treatment were calculated as fold
changes. p-Values were calculated so as to determine whether
the changes in gene expression were significant (Fig. 2). A
multiple testing correction was applied using Benjamini–Hochberg’s
false-discovery rate27 set at 5%. Functional, pathway and network
analyses were performed by using GATHER (Gene Annotation Tool to
Help Explain Relationships28) and IPA (Ingenuity Pathway Analysis29)
software. Networks were ranked by a score that was assigned based
on the probability that a collection of nodes within that network can
occur by chance. A number of networks scored highly, but only the
highest scoring network per cell line – treatment time combination
were presented here so as to avoid biasing results through ‘‘fishing’’
(Fig. S1–S6, ESI†). The network score indicates the likelihood of Focus
Genes in a network being found together, and it is clear from the
high scores that one should be confident that these associations were
not generated by chance.30 IPA constructs networks using a stepwise
process. Networks are constructed in such a way that both inter-
connectivity between Focus Genes and the number of Focus Genes in
the network are optimised (using a network size of 35 or 70 genes/
proteins, as specified in the supplementary figure legends).
3. Results
The four day IC50 concentrations were established for PC3,
DU145 and LNCaP cell lines and the results are listed in Table 1.
With the exception of SN26855, DU145 cells showed the
greatest tolerance to the novel compounds tested. In general,
LNCaP cells appeared to be the most sensitive to the novel
compounds.
Fig. 2 Workflow for microarray analysis of diﬀerential gene expression generated from prostate cancer cells treated with SN30028 (ref. 9 adapted from
ref. 23).
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3.1 HDAC inhibition
Following treatment of cells for 24 h, total protein was extracted.
The eﬀects of compounds of interest on HDAC activity are
shown in Fig. 3–5. The HDAC activity of total protein extracted
from the cell lines, varied from one cell line to another and
varied amongst the novel compounds. HDAC activity of DU145
cells was markedly reduced following treatment with all the
novel compounds, particularly SN30028 (Fig. 4), whilst SN30140
had the largest reduction in HDAC activity in PC3 cells (Fig. 3).
The novel compounds did not appear to reduce HDAC activity in
LNCaP cells (Fig. 5).
3.2 Diﬀerential gene expression (Aﬀymetrix PrimeViewt
Microarrays)
Following the analysis of the Aﬀymetrix PrimeViewtmicroarray
data, it was found that a number of genes in PC3 and DU145 were
diﬀerentially expressed ( p o 0.05; fold change 41.5) following
treatment with SN30028. In total 59, 7 and 64 genes were
up-regulated and 38, 6 and 34 genes were down-regulated in
PC3 at 4, 24 and 96 hours respectively. In DU145 49, 108
and 796 genes were up-regulated and 3, 4 and 399 genes were
down-regulated at 4, 24 and 96 hours respectively. A list of ten
of the most diﬀerentially expressed genes for each cell line–
time point combination, with statistically significant p-values
and a fold change of 41.5 are shown in Table 2 (PC3) and
Table 3 (DU145). The genes listed in the table were selected
based on the absolute fold change and presented from largest
to smallest, regardless of the direction of change.
3.3 Validation of the diﬀerential gene expression data
generated by Aﬀymetrix PrimeViewt microarray
To corroborate the diﬀerential gene expression data generated
by the Aﬀymetrix assay a validation was undertaken by comparing
Table 1 Dosages required to achieve IC50s for PC3, DU145 and LNCaP
cells following four days of treatment with novel and control compounds
Compounds (mM)
PC3 DU145 LNCaP
IC50 IC50 IC50
SN30028 4.58 7.30 0.82
SN30029 2.87 3.82 0.84
SN30140 2.31 3.9 0.71
SN29887 3.61 12.7 6.92
SN29984 7.13 15.66 6.38
SN26855 1.65 0.49 1.11
SAHA 0.88 0.92 0.58
50-Aza-2-deoxycytidine 0.25 0.31 0.53
SAHA = suberoylanilide hydroxamic acid.
Fig. 3 Eﬀect of selected compounds on HDAC activity in PC3 cells.
Fig. 4 Eﬀect of selected compounds on HDAC activity in total protein
extracted from DU145 cells.
Fig. 5 Eﬀect of selected compounds on HDAC activity in total protein
extracted from LNCaP cells.
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the aforementioned data with that obtained from a select number
of genes tested using qRT-PCR. qRT-PCR is widely used for accurate
expression profiling of key genes31 and is a suitable technique to
validate diﬀerential gene expression data generated frommicroarray
experiments. Genes were selected based on a high level of
diﬀerential gene expression in one or more cell line – time
point combinations, an important role in a biological pathway/
network relevant to cancer or inflammation, or effects on
epigenetics.
Gene expression was measured using qRT-PCR in the following
genes: AREG, ARID5B, CDKN2B, CYP1B1, CYP51A1, DHCR7,
DUSP10, EGFR, EPGN, IFIT2, HMGCR, HMGCS1, GULP1, IDI1,
INSIG1, KRT17, LDLR, MMP1, MMP3, NR4A3, PTGS2, RSG4, SCD,
SGK2, SQLE, TM7SF2 and TP53INP1 (Table S1, ESI†). The afore-
mentioned genes were selected based on the level of diﬀerential
gene expression and relevance to cancer/epigenetic mechanisms.
Although the magnitude of change varied between the two
methods with qRT-PCR generating the higher value in general,
the direction of change remained consistent, with the exception
of the gene ARID5B. The gene expression level of ARID5B was
down-regulated according to the results obtained from the
Aﬀymetrix array (fold change of1.82), and up-regulated according
to the results generated by qRT-PCR (fold change of 1.43).
GAPDH and HPRT1 were used as normalisation genes as they
showed consistent results in both PC3 and DU145 cell lines across
the Ct range of the 27 genes tested. Following normalisation, the
fold changes in expression of the selected genes were compared
between those generated from the Aﬀymetrix microarray and those
generated from qRT-PCR experiments (Table S1, ESI†).
3.4 GATHER
GATHER software was used to analyse the relationships between
individual or groups of genes. Only those genes that were
diﬀerentially expressed with a p-value r0.05 and a minimum
fold change of 1.5 were uploaded to GATHER. SN30028 treatment
modulated biological processes and the involved genes are
summarised in Table S2 (ESI†). Those biological processes with
Bayes factors Z3 and p-values r 0.05 were nominated.32 The
Gene Ontology (GO) database was used to obtain definitions of
biological processes.33
The biological processes with the highest Bayes factors
following treatment of PC3 cells with SN30028 at 4, 24 and
96 hours were: the transforming growth factor beta receptor
signalling process (3.53), cyclooxygenase process (4.72), and
response to nutrients process (5.69), respectively. In DU145
cells the sterol biosynthesis and sterol metabolism processes
had the highest Bayes factors at 4 (29.66 and 26.51 respectively)
and 24 hours (51.26 and 49.75 respectively), and cell proliferation
and cell cycle were the most aﬀected biological processes
at 96 hour (25.21 and 21.49 respectively) following SN30028
treatment.
Table 2 The top ten diﬀerentially expressed genes following SN30028 treatment of PC3 cells for 4, 24 and 96 hours
Cell line time Gene symbol Gene name Fold change p-Value (r)
PC3 4 hours MMP3 Matrix metallopeptidase 3 (stromelysin 1, progelatinase) 2.25 2.00  105
HEXA Hexosaminidase A (alpha polypeptide) 2.17 1.07  102
CSF2 Colony stimulating factor 2 (granulocyte-macrophage) 2.16 3.00  104
CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1 2.03 9.20  104
PHC1 Polyhomeotic homolog 1 (Drosophila) 1.96 1.50  104
PNRC1 Proline-rich nuclear receptor coactivator 1 1.91 3.30  104
VNN1 Vanin 1 1.87 7.00  105
RAB5C RAB5C, member RAS oncogene family 1.86 1.06  103
SNORA28 Small nucleolar RNA, H/ACA box 28 1.73 6.40  104
SPEN Spen homolog, transcriptional regulator (Drosophila) 1.73 1.85  102
PC3 24 hours PTGS2 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and
cyclooxygenase)
2.47 4.34  102
EPGN Epithelial mitogen homolog (mouse) 2.26 4.16  102
CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1 2.07 1.25  102
RGS4 Regulator of G-protein signalling 4 1.98 4.34  102
AREG Amphiregulin 1.87 3.80  102
GULP1 GULP, engulfment adaptor PTB domain containing 1 1.83 4.10  102
SC4MOL Sterol-C4-methyl oxidase-like 1.76 1.12  102
SGK2 Serum/glucocorticoid regulated kinase 2 1.76 1.85  102
RNF144A Ring finger protein 144A 1.75 1.25  102
KRT17 Keratin 17 1.71 4.16  102
PC3 96 hours SCNN1G Sodium channel, non-voltage-gated 1, gamma 2.92 1.72  102
DDIT3 DNA-damage-inducible transcript 3 2.77 4.57  102
CXCR7 Chemokine (C–X–C motif) receptor 7 2.49 3.12  102
CHRNA1 Cholinergic receptor, nicotinic, alpha 1 (muscle) 2.38 2.13  102
HERPUD1 Homocysteine-inducible, endoplasmic reticulum stress-inducible,
ubiquitin-like domain member 1
2.11 3.67  102
STC1 Stanniocalcin 1 2.10 4.22  102
TMSB15A Thymosin beta 15a 2.04 2.40  102
HSPA5 Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) 2.04 2.86  102
SESN2 Sestrin 2 1.98 3.12  102
AREG Amphiregulin 1.95 3.12  102
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3.5 Ingenuity pathways analysis
IPA software (IPAs, QIAGEN Redwood City, USA) was used to
transform a list of genes into a set of relevant networks29 and
this software is widely used for biological pathway, function
and disease, and molecular network analysis.34,35 All results
from each time-point-cell line combination were submitted to
IPA with the filters and settings as follows: adjusted p-value of
0.05 and fold-change of 1.5. The most significantly aﬀected
canonical pathways and associated network functions in
response to treatment by SN30028 at three time points in PC3
and DU145 cell lines generated through IPA are shown in
Table 4. Using Fischer’s exact test, the results were ranked.
The ratios listed in the table represent the number of genes in
the dataset that were in the canonical pathway stated, divided
by the total number of genes in that particular pathway.
Obtaining a list of genes and related pathways is informative,
but it is the identification of the connections between the path-
ways that is important. The IPA networks are assembled based on
connectivity between genes. Several networks were generated by
IPA software from each microarray experiment using the IPA
knowledge base, but only the strongest network for each cell line
– time point combination are shown here (Fig. S1–S6, ESI†). The
scores of the IPA network indicate how relevant the network is to
the genes in the uploaded dataset (Score = log10( p-value)). It is
evident from Table 4 that cancer-related pathways are highly
affected by SN30028 treatment in both cell lines. The parameters
were set at either 70 or 35 molecules per network and a direct
interaction between the molecules. Only relevant genes with an
adjusted p-value o0.05 and fold change 41.5 or o1.5 were
selected for network analysis.
IPA generated results regarding the most prominent diseases
and functions associated with the network depicted in Fig. S1–S6
(ESI†). These diseases and functions included developmental
disorders, cancer, inflammatory disorders, cell death and survival,
cellular growth and proliferation, cellular function andmaintenance
and DNA replication amongst others. Using the Fisher’s exact test
IPA calculates a network score which is the log10 of the p-value of the
network.29 The network scores ranged from 38 (Fig. S2, ESI†) to 84
(Fig. S6, ESI†) and between 13% (Fig. S2, ESI†) and 100% (Fig. S6,
ESI†) of the genes in each network were differentially expressed.
4. Discussion
Regulation of gene expression is encoded by the genome and by
the epigenome. The focus of this discussion is on themodulation of
gene expression and the molecular interaction of diﬀerentially
Table 3 The top ten diﬀerentially expressed genes following SN30028 treatment of DU145 cells for 4, 24 and 96 hours
Cell line time Gene symbol Gene name Fold change p-Value (r)
DU145 4 hours INSIG1 Insulin induced gene 1 2.74 2.03  102
ULBP1 UL16 binding protein 1 2.24 2.02  103
HMGCS1 3-Hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) 2.17 3.71  102
DDIT4 DNA-damage-inducible transcript 4 2.07 2.03  102
BDP1 B double prime 1, subunit of RNA polymerase III transcription initiation
factor IIIB
2.06 3.00  102
SC4MOL Sterol-C4-methyl oxidase-like 2.01 2.03  102
LPIN1 Lipin 1 1.95 5.55  103
EGFR Epidermal growth factor receptor 1.94 3.53  102
CEP350 Centrosomal protein 350 kDa 1.91 2.29  102
MLL3 Myeloid/lymphoid or mixed-lineage leukemia 3 1.89 1.24  102
DU145 24 hours IFIT2 Interferon-induced protein with tetratricopeptide repeats 2 3.09 2.23  103
HMGCS1 3-Hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) 3.02 9.05  103
SC4MOL Sterol-C4-methyl oxidase-like 3.01 4.72  104
IFIT3 Interferon-induced protein with tetratricopeptide repeats 3 2.98 1.34  102
INSIG1 Insulin induced gene 1 2.89 2.14  103
IFIT1 Interferon-induced protein with tetratricopeptide repeats 1 2.82 4.72  104
AKR1B10 Aldo-keto reductase family 1, member B10 (aldose reductase) 2.58 2.21  103
IFI44 interferon-induced protein 44 2.52 1.71  102
OASL 20-50-Oligoadenylate synthetase-like 2.44 4.72  104
DDX60 DEAD (Asp–Glu–Ala–Asp) box polypeptide 60 2.41 5.30  103
DU145 96 hours MMP1 Matrix metallopeptidase 1 (interstitial collagenase) 7.00 8.28  106
S100A9 S100 calcium binding protein A9 5.47 1.96  104
IGFBP3 Insulin-like growth factor binding protein 3 5.41 2.92  105
C3 Complement component 3 4.79 7.94  105
SLPI Secretory leukocyte peptidase inhibitor 4.51 3.21  104
GKN2 Gastrokine 2 4.50 9.97  106
AKR1C1 Aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1;
20-alpha (3-alpha)-hydroxysteroid dehydrogenase)
4.47 1.04  103
CDH1 Cadherin 1, type 1, E-cadherin (epithelial) 4.39 1.69  104
CYP4F11 Cytochrome P450, family 4, subfamily F, polypeptide 11 4.08 2.99  104
AKR1C1///AKR1C2 Aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1;
20-alpha (3-alpha)-hydroxysteroid dehydrogenase)///aldo-keto reductase
family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding
4.06 1.12  103
AKR1C2 Protein; 3-alpha hydroxysteroid dehydrogenas
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Table 4 The top canonical pathways, diseases and functions aﬀected by SN30028 treatment at three time points in PC3 and DU145 cell lines
PC3 Top canonical pathways p-Value Diﬀerentially expressed genesa Ratio
4 hours Glucocorticoid receptor signalling 2.76  104 BCL2, CSF2, NCOR2, MMP1, PTGS2 7/272
Docosahexaenoic acid (DHA) signalling 7.88  104 BCL2, BIK, FOXO1 3/39
Chondroitin sulfate degradation 1.61  103 HEXA, MGEA5 2/13
Dermatan sulfate degradation 1.88  103 HEXA, MGEA5 2/14
PI3K/AKT signalling 2.46  103 BCL2, FOXO1, GDF15, PTGS2 4/121
Associated network functions Score
Developmental disorder, cell death and survival, organismal injury and
abnormalities.
60
Cellular growth and proliferation, cell death and survival, cancer. 56
Cellular development, cellular growth and proliferation, haematological
system development and function.
37
Post-translational modification, cancer, gastrointestinal disease. 2
Cell morphology, cellular function and maintenance, DNA replication,
recombination, and repair.
2
PC3 Top canonical pathways p-Value Diﬀerentially expressed genesa Ratio
24 hours Role of IL-17A in arthritis 5.43  104 MMP1, PTGS2 2/54
Zymosterol biosynthesis 3.89  103 MSMO1 1/6
Airway pathology in chronic obstructive pulmonary disease 5.18  103 MMP1 1/8
Prostanoid biosynthesis 5.83  103 PTGS2 1/9
Cholesterol biosynthesis I 8.41  103 MSMO1 1/13
Associated network functions Score
Cancer, dermatological diseases and conditions, tissue morphology. 38
PC3 Top canonical pathways p-Value Diﬀerentially expressed genesa Ratio
96 hours Unfolded protein response 1.52  104 DDIT3, DNAJB9, HSPA5, INSIG1 4/53
Superpathway of cholesterol biosynthesis 3.41  104 ACAT2, HMGCS1, SQLE 3/27
Ketogenesis 1.12  103 ACAT2, HMGCS1 2/10
Mevalonate pathway I 1.63  103 ACAT2, HMGCS1 2/12
Superpathway of geranylgeranyl-diphosphate biosynthesis I 2.93  103 ACAT2, HMGCS1 2/16
Associated network functions Score
Cancer, organismal injury and abnormalities, neurological disease. 46
Cardiovascular disease, hereditary disorder, metabolic disease. 30
Lipid metabolism, molecular transport, small molecule biochemistry. 30
Cell-to-cell signalling and interaction, cellular assembly and organization,
cellular function and maintenance.
30
Cancer, endocrine system disorders, organismal injury and
abnormalities.
28
DU145 Top canonical pathways p-Value Diﬀerentially expressed genesa Ratio
4 hours Superpathway of cholesterol biosynthesis 4.03  1015 HMGCR, MSMO1, MVK, SC5D, SQLE 8/27
Cholesterol biosynthesis I 1.66  1010 DHCR7, MSMO1, NSDHL, SC5D, SQLE 5/13
Cholesterol biosynthesis II 1.66  1010 DHCR7, MSMO1, NSDHL, SC5D, SQLE 5/13
Cholesterol biosynthesis III 1.66  1010 DHCR7, MSMO1, NSDHL, SC5D, SQLE 5/13
Mevalonate pathway I 4.28  106 HMGCR, HMGCS1, MVK 3/12
Associated network functions Score
Cancer, cell morphology, cellular function and maintenance. 43
Cardiovascular disease, metabolic disease, lipid metabolism. 35
Drug metabolism, small molecule biochemistry, cellular assembly
and organization.
35
DU145 Top canonical pathways p-Value Diﬀerentially expressed genesa Ratio
24 hours Superpathway of cholesterol biosynthesis 3.25  1032 HMGCS1, MSMO1, SC5D, HSD17B7, SQLE 17/27
Cholesterol biosynthesis I 1.53  1023 MSMO1, SC5D, HSD17B7, SQLE, TM7SF2 11/13
Cholesterol biosynthesis II 1.53  1010 MSMO1, SC5D, HSD17B7, SQLE, TM7SF2 11/13
Cholesterol biosynthesis III 1.53  1010 MSMO1, SC5D, HSD17B7, SQLE, TM7SF2 11/13
Zymosterol biosynthesis 4.07  106 CYP51A1, HSD17B7, MSMO1, NSDHL, TM7SF2 5/6
Associated network functions Score
Lipid metabolism, small molecule biochemistry,
vitamin and mineral metabolism.
66
Carbohydrate metabolism, lipid metabolism, small
molecule biochemistry.
63
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expressed genes, represented in the form of networks, generated
using transcriptomics and analysed using IPA. The most common
pathways, as shown in Table 4, will be examined. Similarly, central
nodes in networks will be discussed if they are evident in more than
one network.
Novel compounds were used to treat prostate cancer cell
lines, inhibition of cell proliferation was observed and HDAC
activity was assessed to determine which compound-cell line
combination to use in the transcriptomics experiments. DU145
was found to be more tolerant to the novel compounds than
PC3 and LNCaP, and LNCaP was found to be the most sensitive
to the novel compounds with respect to cell proliferation. In
contrast, DU145 had the greatest response to the novel compounds
with respect to HDAC inhibition, whereas LNCaP had the least or no
inhibitory response to these compounds. In addition, there was
a far greater response observed in DU145 than in PC3 when
considering the number of genes diﬀerentially expressed, as
well as the size of the response.
There are a number of phenotypic and genotypic diﬀerences
amongst PC3, DU145 and LNCaP. LNCaP is androgen sensitive,
whilst PC3 and DU145 are androgen independent. HDAC
inhibitors interfere with androgen receptor activity36 and therefore
it is likely that the cell lines would respond diﬀerently. Seeing that
PC3 and DU145 are androgen independent, it was not surprising
that a change in the AR gene was not observed.
In addition to androgen sensitivity, the three cell lines of interest
also diﬀer with regards to TNFb. When treated with TNFb, cell
proliferation was initially inhibited, whilst no eﬀect was observed in
LNCaP cells.37 TGFb induces epigenetic changes to modulate
cell proliferation, diﬀerentiation and migration, and TGFb may
initiate cellular changes that facilitate its role as both a tumour
suppressor during the early stages of tumour development, and
as a tumour promoter in metastatic or later stage disease.5
HDAC inhibitors may inhibit the activation of TGFb in epithelial
cells5 by blocking TGFbmediated epithelial-mesenchymal transition
(EMT), which is essential for cell growth and invasion.38 In our study
we found that TGFb was down regulated in response to SN30028,
with fold changes between 1.074 and 1.707 (adjusted p values were
significant for DU145 96 h treatment only).
4.1 Biological processes and pathways
Based on the transcriptomics results and analysis using GATHER
and IPA, a number of cancer related ‘‘biological processes,’’ and
‘‘network associated functions’’ were aﬀected by SN300028
treatment of the prostate cancer cell lines, DU145 and PC3 at
all three time points tested (Table 4). Using GATHER, the most
commonly modulated biological processes in DU145 (with high
Bayes factor values) were in relation to sterol and cholesterol
metabolism and biosynthesis (Table S2, ESI†) at the 4 and 24 h
time points, whilst at 96 h the more directly cancer related
biological processes of cell proliferation, cell cycle and DNA
replication were evident. This is consistent with data generated
using IPA. The top canonical pathways generated using IPA
included those related to cholesterol biosynthesis (PC3 – 24 and
96 h, and DU145 – 4 and 24 h) and themevalonate pathway (PC3
– 96 h and DU145 – 4 h).
Other studies have been carried out using gene expression
arrays, or targeted gene expression to assess levels of gene
expression in normal versus adenocarcinoma or precursor
adenocarcinoma tissues as well as in cell lines in response to
HDAC inhibitors.39–43 Variations were observed in different
cancer cell lines in response to HDAC inhibitors, with, in some
cases, non-overlapping cellular targets.43 Using different cell
lines and a different HDAC inhibitor, it is not surprising that
Table 4 (continued )
DU145 Top canonical pathways p-Value Diﬀerentially expressed genesa Ratio
Lipid metabolism, small molecule biochemistry,
vitamin and mineral metabolism.
60
Antimicrobial response, inflammatory response,
infectious disease.
23
DU145 Top canonical pathways p-Value Diﬀerentially expressed genesa Ratio
96 hours Molecular mechanisms of cancer 7.24  107 RHOU, CDH1, SHC1, BBC3, PLCB4 46/359
Cell cycle control of chromosomal replication I 1.75  106 ORC6, CDC6, CDT1, CDC45, MCM2 10/27
Estrogen-mediated S-phase entry 5.18  106 CCNE2, CDKN1B, E2F5, CCND1, CDK1 9/24
Glioblastoma multiforme signaling I 1.49  105 RHOU, SHC1, PLCB4, PLCB1, PTEN 23/145
Glioma signaling 3.45  105 SHC1, PTEN, IGF1R, PRKCA, PA2G4 17/94
Associated network functions Score
Skeletal and muscular system development and function, protein
synthesis, cellular compromise.
84
Cellular development, cellular growth and proliferation, digestive
system development and function.
77
Post-translational modification, cell cycle, hair and skin development
and function.
73
Cell cycle, cellular assembly and organization, DNA replication,
recombination, and repair.
68
DNA replication, recombination, and repair, cell cycle, connective
tissue disorders.
67
Ratio = diﬀerentially expressed genes/total number of genes in that pathway. a = up to five genes with the smallest p-values were selected.
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different pathways were modulated, although some overlap was
observed with respect to modification of gene expression.
Cholesterol metabolism plays an important role in providing
cells with compounds for growth and sterol biosynthesis is an
essential metabolic component of cancers.44 In addition, over-
expression of cholesterol biosynthesis pathways has been previously
detected in refractory breast cancers45 and this is consistent with the
data observed from themetastatic prostate cancer cell lines we tested.
More specifically, cytochrome P450 1B1 (CYP1B1) is important for the
synthesis of cholesterol steroids and lipids, and is well known for its
role in drug metabolism.46 CYP1B1 activity is inhibited by a number
of anti-cancer agents and is commonly over-expressed in a variety of
tumours.47 In our study the expression of CYP1B1 was down
regulated in PC3 cells treated for 4 and 24 h, and it is suggested
that the inhibition of CYP1B1 is brought about through the
inhibition of HDAC6 activity.48 In contrast, inconsistencies have
arisen, for example the HDAC inhibitors SAHA and TSA induced
CYP1B1 expression in the human breast cancer MCF-7.49
Themevalonate pathway has a broad influence and is associated
with the cholesterol related biosynthesis pathways; is important in
cellular metabolism; plays a role in the maintenance of cell
membranes; is involved in steroid biosynthesis and can be
disrupted by medication prescribed for bone-density disorders
and high cholesterol levels.50,51 In addition, the mevalonate
pathway is an important target for anti-cancer therapy and
inhibitors of this pathway target malignant cell growth50,51
and are believed to act through the modification of methylation
status of CpG sites in gene promoter regions involved in
apoptosis and/or cell proliferation.52 In addition, DU145 cells,
after 96 hours of treatment, showed the top canonical pathway
aﬀected was ‘‘molecular mechanisms of cancer’’ with 46 of the
359 genes involved were diﬀerentially expressed.
All cell line – treatment time combinations showed cancer to
be one of the top five diseases and disorders, with the exception
of DU145 at 24 h with a closely related disease/disorder, namely
inflammatory response listed in the top five. The number of
cancer related genes that were differentially expressed for each
cell line – treatment time combination ranged from11 to 445 genes
with p values ranging from 8.00  102 to 2.15  1017. It is clear
that numerous cancer related genes were differentially expressed
in prostate cancer cell lines in response to treatment and therefore
the compound, SN30028 is of interest. Similarly, Chang et al.
found that a large number of genes were differentially expressed in
response to the HDAC inhibitor, TSA, in non-small cell lung
cancer.43 However, in the study by Chang et al.,43 the fold-
changes observed were much higher than those reported here.
‘‘Associated network functions’’ were also listed as an output
from IPA for each cell line – treatment time combination. Cell cycle,
cellular growth and proliferation, DNA replication and repair,
inflammatory response, and cancer all ranked highly in one or
more of the cell line – treatment time combinations and thus it is
evident that SN30028 has an impact on cancer related mechanisms.
4.2 Networks
The networks shown in Fig. S1 and S2 (ESI†) demonstrate that
prostaglandin H synthase (PTGS2), otherwise known as COX2,
connects with many genes in networks generated from PC3 treated
for 4 and 24 hours and was one of the top ten diﬀerentially
expressed genes following PC3 treatment for 4 h (Table 2). The
down regulation of COX2was corroborated in qRT-PCR experiments
(Table S1, ESI†). COX2 is down-regulated by treatment with
SN30028 for 4 and 24 hours (PC3) by a fold change of 1.71 and
2.47 respectively. COX2 plays a key role in prostanoid production
by catalysing the conversion of arachidonic acid to prostaglandin
G2 and H2 resulting in an inflammatory response.53,54 Numerous
studies have been conducted to investigate COX2 inhibition and the
reduction in inflammatory response55 and its role in oncogenesis.56
Non-steroidal anti-inflammatory drugs are a class of drugs that
inhibit COX2 enzyme activity and thereby reduce the inflammatory
response.57,58 This supports the notion that SN30028 has anti-
inflammatory eﬀects.
Matrix metalloproteinase 3 (MMP3) was initially up-regulated
in PC3 cells treated with SN30028 (Table 2 and Fig. S1, ESI†),
but this response was not maintained. In addition, although
MMP3 acts on a number of diﬀerent genes, the expression of
these genes was not modified when MMP3 was up-regulated
(Fig. S1, ESI†). Although MMP3 is over-expressed in most
human cancers, and is known to induce initial cancer cell-growth
and diﬀerentiation, rather than act at a later stage in cancer
progression,59,60 it is also known to havemany opposing functions59
and to date MMP inhibitors have not been successful in the clinic.60
Diﬀerential expression of numerous other central node or
core genes is evident, but none of the central node genes arise
in more than two top ranked networks representing each cell
line – treatment time combination. Some of the differentially
expressed central node genes include FOXO1 and 3, thought to
be involved in triggering apoptosis or cell survival and are
induced by oxidative stress;61 amphiregulin (AREG) was down-
regulated in PC3 (Fig. S2 and S3, ESI†) supporting the idea that
SN30028 reduces inflammation and inhibits tumour development.62
AREG is a ligand of epidermal growth factor receptor (EGFR)62 and
the fact that EGFR is up-regulated in DU145 (Fig. S4, ESI†) could
either be a chance occurrence as this finding was only attained
in DU145 treated for 4 h and therefore is an initial response that
is not sustained, or it could be that SN30028 works through
different mechanisms in the two cell lines. Up-regulation of
EGFR is associated with prostate cancer progression and EGFR
dysfunction induces cell survival, proliferation, invasion and
metastasis and therefore was not an anticipated response. The
AR gene is known to interact with EGFR and we wouldn’t expect
to see a change in expression as DU145 and PC3 are androgen
insensitive. However, although these cell lines are regarded as
androgen non-responsive, some authors have reported low level
expression of AR mRNA, and treatment with interferon (IFN)
resulted in up-regulation of AR protein levels.63 This may be due
to AR phosphorylation. In the experiments reported herein a
change in AR expression in response to treatment with SN30028
was not noted.
Similar to the unexpected up-regulation of EGFR, the ETS-
related gene (ERG) was up-regulated (at low intensity) after 96 h
(Fig. S6, ESI†) and is an unexpected response. ERG is a proto-
oncogene, regulates cell proliferation, diﬀerentiation, angiogenesis,
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inflammation, apoptosis and can result in gene fusion products
associated with prostate and other cancers.64 ERG, when over-
expressed, is able to regulate oncogenic pathways involving
cMyc, AR and EZH2,64 none of which were up-regulated in this
study. ERG acts on neuronally expressed developmentally down-
regulated 4 (NEDD4),64 which is a central node gene that was
down-regulated in DU145 cells (Fig. S6, ESI†). NEDD4 is an
oncoprotein that promotes degradation through the ubiquiti-
nation of its substrates and it is also thought to promote colon
and lung carcinogenesis, be over-expressed in prostate, breast
and bladder cancers, and promotes growth of colon cancer cells
independently of PTEN and PI3K/AKT signalling.65 Despite the
fact that ERG is over-expressed in DU145 after 96 h of treatment
and acts on NEDD4 (amongst other genes), SN30028 appears to
inhibit NEDD4 which is desirable, although further work is
required for the elucidation of the mechanisms involved in
treating cancers in this way.
5. Conclusions
In conclusion SN30028, an HDAC inhibitor was synthesised and used
in the treatment of prostate cancer cell lines for 4, 24 and 96 h, and
assessed for diﬀerential gene expression. Using IPA software the data
were analysed and pathways involved in cholesterol biosynthesis and
mevalonate were aﬀected most commonly in the cell line DU145. In
addition to pathway and network analysis themost frequently aﬀected
diseases and disorders were assessed. Those related to inflammatory
response and/or cancers were one of the top five diseases and
disorders listed for each cell line-time point tested. SN30028 showed
it could be a potential therapeutic agent in treating prostate cancer
by targeting the sterol and mevalonate pathways, however
further work is required to confirm these results.
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